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Background: Human cytomegalovirus (CMV) is a lifelong, often asymptomatic infection, with the virus
maintained in latently infected myeloid cells. Patients receiving chemotherapy for cancer are at high risk
of reactivation of latent CMV, which may further contribute to host immune exhaustion, ultimately
leading to a poor antitumor response. Pre-emptive anti-CMV medication may, therefore, serve as an
adjunct therapy, preventing deterioration of the patient’s immunity during treatment for cancer. The
present study evaluated ganciclovir treatment’s in vitro effects on CMV-associated T cell exhaustion and
the antitumor capacity of cells from cancer patients.
Methods: Peripheral blood mononuclear cells from patients with various types of cancers were treated
with or without ganciclovir. Cells were then analyzed for T cell subpopulations and activation markers
using ﬂow cytometry, and their antitumor capacity was tested after exposure to dendritic celleA549
fusion cells.
Results: Following ganciclovir treatment, there was a redistribution of T cell subpopulations which was
clearly distinct from the baseline pattern of T cell exhaustion. Treatment resulted in increases in early
differentiated proportions, including naive (untreated control cells vs. ganciclovir treated cells,
p < 0.001), interleukin (IL)-7Raþ (p < 0.01), and CD28þCD8þ (p < 0.05) T cells, and a decrease in the
proportion of effector memory (p < 0.001) T cells in cancer patients. Ganciclovir treatment signiﬁcantly
improved tumor-killing capacity (p < 0.001), with a concomitant downregulation of T cell exhaustion
marker programmed death-1 (PD-1) (p < 0.001).
Conclusion: These ﬁndings demonstrate that ganciclovir treatment in vitro directly affects immune
function by partially reconstituting T cell subsets and restoring the T cell antitumor response.
Copyright  2012, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Human cytomegalovirus (CMV) is a herpesvirus which ubiqui-
tously infects humans. More than 70% of the world’s population are
chronic carriers1,2. Primary CMV infection is usually asymptomatic
in healthy adults and, for many years, investigators did not consider
CMV to be a major human pathogen. A hallmark of the clinically
signiﬁcant CMV infection is its capacity to induce recurrent disease.terest.
Medical Department, Mackay
Road, Taipei, Taiwan.
iwan Society of Geriatric EmergenReactivation of latent CMV infection is amajor cause of morbidity in
patients who are immunocompromised by human immunodeﬁ-
ciency virus infection, malignancies, organ transplants or immu-
nosuppressive therapy.
In our previous study, nearly 90% of patients receiving cancer
chemotherapy experienced CMV reactivation during the course of
chemotherapy, with the average viral load peaking after the third
course of treatment3. Following chemotherapy, reactivation of CMV
infection left a signiﬁcantly enhanced number of circulating CMV-
speciﬁc T cells. In heavily treated patients with terminal cancer,
decreases in the populations of early differentiated T cells, such as
naive and central memory T cells, was associated with increases in
CMV-speciﬁc T cells. These changes may, in turn, have resulted in
hyporesponsive immunity4, as a result of the functional aberrationcy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
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highly resistant to apoptosis, with large clonal populations per-
sisting for years5; they accumulate progressively throughout life. At
the same time, irreversible loss of CD28þ cells may also occur, and
the proliferation of these is limited or may cease completely6. In
addition, the surface expression of interleukin (IL)-7Ra was
inversely related to the intracellular CMV load, and downregulation
of IL-7Ra was associated with decreases in the naive T cell pop-
ulation in cancer patients4. Many virus-speciﬁc persistent T cells
which recognize latent herpesvirus lack IL-7Ra expression7. CMV
reactivates in most cancer patients undergoing chemotherapy,
therefore IL-7Ra T cells may survive and increase in number as
a result of regular CMV antigen stimulation. The clonal expansion of
CMV-speciﬁc T cells may, thus, shrink the repertoire of immune
cells available for other antigens, resulting in chemotherapy-
associated deterioration of immune function8,9.
Ganciclovir is a synthetic analogue of 20-deoxyguanosine, which
inhibits the replication of herpesviruses. It is thought to mediate its
antiviral activity through the inhibition of viral DNA synthesis, by
competitively inhibiting the incorporation of deoxyguanosine
triphosphate intoviralDNA, resulting in the terminationof viralDNA
elongation10. It is the gold standard antiviral drug effective in the
treatment of CMV-associated diseases in humans11. Given the high
incidence of CMV reactivation in cancer patients, pre-emptive anti-
CMVtreatmentmay, therefore, be of potential use in cancerpatients.
Nevertheless, several studies have demonstrated that ganciclovir
directly inhibits lymphocyte proliferation induced by various
stimuli12,13. Thus, the present in vitro study aimed to evaluate the
immunomodulatory effect of ganciclovir on patients’ T cell pools.
2. Materials and methods
2.1. Subjects
Patients receiving treatment for various types of cancer at
Mackay Memorial Hospital were selected (Table 1). All were sero-
positive for CMV immunoglobulin G (IgG). None of the study
participants received immunotherapy at the time at which blood
samples were collected, but all had received chemotherapy
according to the standard treatment regimen for their speciﬁc
cancer. Healthy volunteers were also recruited to provide blood
samples for comparison. This study was approved by the Institu-
tional Review Board at Mackay Memorial Hospital (Taipei, Taiwan),
and written informed consents were obtained from all participants.
2.2. Reagents and cell line
Ganciclovir (Cymevene) was purchased from Roche Products
(New Zealand) and reconstituted by injecting sterile water. IL-2
(Proleukin, Basel, Swizerland) and IL-7 were purchased from
Chiron (Amsterdam, Netherlands) and R&D systems (Minneapolis,
MN, USA), respectively. A human nonsmall cell lung carcinoma line,
A549, was obtained from the Bioresource Collection and Research
Center (HsinChu, Taiwan) and maintained in F12K medium (Gibco
Invitrogen, Grand Island, NY, USA), 10% heat-inactivated fetal calf
serum (FCS) (Biological Industries, Israel), penicillin (100 U/mL),Table 1
Clinical characteristics of patients.
Cancer Number Sex (male/female) Age (y) (mean  SD)
Respiratory system 12 9/3 60  16
Digestive system 8 4/4 58  12
Head and neck 8 2/6 62  9
Reproductive system 17 16/1 53  9
Total 45 31/14 58  12and streptomycin (100 mg/mL) at 37C in a 5% CO2 humidiﬁed
atmosphere.
2.3. Processing of peripheral blood mononuclear cells and
ganciclovir treatment
Approximately 3e5 mL blood was collected from each partici-
pant in a tube containing ethylenediaminetetraacetic acid (EDTA).
Peripheral blood mononuclear cells (PBMCs) were isolated from
whole blood using Ficoll-Paque PLUS (Amersham Biosciences AB,
Uppsala, Sweden) gradient centrifugation. PBMCs from each
patient were divided into two groups: untreated control cells and
cells to be treated with ganciclovir. Both groups were cultured in
RPMI 1640 medium (Hyclone, Logan, UT, USA) supplemented with
10% FCS, 20 IU/mL IL-2, and 5 ng/mL IL-7. For the treated cells,
a dose of 7.5 mg/mL ganciclovir was chosen to reproduce typical
levels (w0.5e10 mg/mL) achieved in the sera of patients treated
with ganciclovir14. Sterile water served as vehicle control. The
culture medium was replaced every day until Day 10.
2.4. Flow cytometric analysis
Cultured cells were stained using antibodies against CD8 (FITC,
clone HIT8a), CD28 (PE, clone CD28.2), CD45RA (APC, clone HI100),
CD127 (IL-7Ra) (PE, clone hIL-7R-M21), programmed death-1
(PD-1) (FITC, clone MIH4), CD8 (PerCP, clone SK1) (BD, San
Jose, CA, USA), CCR7 (FITC, clone 150503) (R&D Systems, Minne-
apolis,MN, USA), or appropriate isotype-control antibodies (BD, San
Jose, CA, USA). Lymphocytes were gated on the basis of their
Forward scatter/side scatter (FSC/SSC) properties. After 10 days of
culturing, the purity of CD3þ T cells in lymphocyte populations was
greater than 90% (data not shown). The expression of CD45RA and
CCR7 was used to determine T cell subsets, as described by Sallusto
et al15, among thecontrolandganciclovir-treatedPBMCs fromhealthy
volunteers or patients with cancer. Stained cells were acquired
using FACS Calibur (BD, San Jose, CA, USA). Analysis was performed
using FCS EXPRESS 3.0 (De Novo software, Thornhill, ON, Canada).
2.5. Electrofusion of dendritic cells and A549 tumor cells
Monocyte-derived dendritic cells (DCs) were generated using an
adherencemethod described previously16. On Day 5, immature DCs
were matured using 10 ng/mL tumor necrosis factor TNF-a (R&D
Systems, Minneapolis, MN, USA) for 2 days, then used in fusion
experiments. DCs and UV-irradiated A549 cells (50 J; Stratalinker
UV Crosslinker 1800, 254 nm) were mixed at a 1.2:1 ratio and
suspended in a hypotonic solution containing 0.1mMCa (CH3COO)2,
0.5mMMg(CH3COO)2, and 75mM sorbitol (Sigma-Aldrich, St. Louis,
MO, USA)17. A pulse generator (model ECM 2001, BTX Instruments,
Genetronics, San Diego, CA, USA) was used for electrofusion. Cell
alignment was ﬁrst induced using dielectrophoresis with an alter-
nating current (AC) pulse of 35 V/cm for 9 seconds. Subsequently,
cell fusion was triggered using a single square wave direct current
pulse of 750 V/cm for 30 microseconds. The fusion mixture
was allowed to rest overnight in AIM-V medium and then puriﬁed
by human leukocyte antigen (HLA)-DR selection using HLA-DR
MACS microbeads (Miltenyi Biotec, Auburn, CA, USA).
2.6. Cytotoxicity assay
Cells (1  105 cells/well) treated with, or without, ganciclovir
were incubated for 5 days with DC-A549 cells (2  103 cells/well).
The allogeneic cytotoxicity of in vitro-stimulated responder cells
against A549 cells was measured using the CytoTox 96 Non-
Radioactive Cytotoxicity Assay (Promega, Madison, WI, USA). The
Ganciclovir Improves Immune Status 173assays were performed according to the manufacturer’s protocol.
Results are presented as the percentage of lysis according to the
following formula:
% of lysis ¼ 100  (Experimental e Effector Spontaneous e Target
Spontaneous)/(Target Maximum e Target Spontaneous)
2.7. Statistical analysis
Comparisons between groups were performed using a Student t
test. Differences were considered to be signiﬁcant when p < 0.05.
Data were analyzed using Prism version 4 (GraphPad, La Jolla, CA,
USA).
3. Results
3.1. Reconstitution of T cell subpopulations in ganciclovir-treated
cells
In vitro treatment of PBMCs from healthy volunteers and cancer
patients with, or without, 7.5 mg/mL ganciclovir for 10 days was
evaluated to determine whether or not ganciclovir treatment
affected T cell subpopulations. Fig. 1A displays the representative
FACS plots of T cell subpopulations from cancer patients. In cancer
patients, the proportion of naive T cells in the ganciclovir-treated
group (21.51  15.23% of lymphocytes) was signiﬁcantly higher
than that in the untreated control group (12.74  13.96% of
lymphocytes; p< 0.001). Ganciclovir treatment had no effect on the
proportion of central memory T cells (control: 22.33  8.95% vs.Fig. 1. Alterations to T cell subpopulations following in vitro ganciclovir treatment.
PBMCs of healthy volunteers (n ¼ 10) and cancer patients (n ¼ 27) were treated with
ganciclovir in vitro then analyzed using ﬂow cytometry after 10 days. The expression of
phenotypic markers, CD45RA and CCR7, identiﬁed naive, central memory, effector
memory, and effector subpopulations. (A) Representative FACS plots of T cell subpopu-
lations 10 days after ganciclovir treatment. (B) Relative percentages of T cell subpopu-
lations. The data are representative of ﬁve independent experiments, and are presented
asmeanSD%of lymphocytes. *p<0.05. **p<0.01. ***p<0.001. CM¼ centralmemoryT
cells (CD45RACCR7þ); Effector ¼ effector T cells (CD45RAþCCR7); EM ¼ effector
memory T cells (CD45RACCR7); N ¼ healthy volunteers; Naïve ¼ naive T cells
(CD45RAþCCR7þ); ns ¼ not signiﬁcant; Pt ¼ cancer patients.ganciclovir: 24.3411.12% of lymphocytes ; p¼ 0.197). However, the
proportion of effector memory T cells in the ganciclovir-treated
group markedly decreased (control: 47.71  18.51 vs. ganciclovir:
29.86  12.88% of lymphocytes; p < 0.001), whereas the proportion
of effector T cells increased after ganciclovir treatment (control:
17.21  12.08 vs. ganciclovir: 24.28  13.76% of lymphocytes;
p < 0.01) (Fig. 1B). Similar patterns were observed in PBMCs from
healthy volunteers. The ganciclovir-treated group contained signiﬁ-
cantly higher proportions of naive T cells (control: 10.53  6.67 vs.
ganciclovir: 23.48  8.57% of lymphocytes; p < 0.001). The propor-
tion of central memory cells slightly increased following ganciclovir
treatment (control: 26.65  9.56 vs. ganciclovir: 31.25  6.52% of
lymphocytes; p¼ 0.03), and the proportion of effector memory cells
signiﬁcantly decreased following ganciclovir treatment (control:
50.55  18.54 vs. ganciclovir: 25.51  14.04% of lymphocytes;
p<0.001). Theproportionof effectorTcells in theganciclovir-treated
groupwas higher than in the control group (control: 12.29 7.03 vs.
ganciclovir: 19.75  2.59% of lymphocytes; p ¼ 0.001). These results
indicate that ganciclovir treatment in vitro may directly modify T
cell subsets, leading to increases in naive T cells and the continuing
differentiation of effector memory cells into effector T cells, but
without affecting the pool of central memory T cells.
3.2. Expression of IL-7Ra and PD-1 following ganciclovir treatment
Our previous study has shown that downregulation of IL-7Ra
was associated with decreases in naive T cell populations in cancer
patients4. The current study further evaluated the expression of IL-
7Ra in ganciclovir-treated cells. Fig. 2A, upper panel, displaysFig. 2. Expression of IL-7Ra and PD-1 in ganciclovir-treated cells. Untreated control
and ganciclovir-treated cells (n ¼ 14e19/group) from healthy volunteers and cancer
patients were further stained with anti-IL-7Ra or anti-PD-1 antibodies to detect
surface expression of IL-7Ra and PD-1. (A) Representative FACS histograms of T cells in
the presence or absence of ganciclovir treatment (heavy line histogram, ganciclovir;
thin line histogram, control; dash line histogram, appropriate isotype control). (B)
Percentages of IL-7Raþ and PD-1þ T cells in untreated control and ganciclovir-treated
cells. Data are representative of ﬁve independent experiments and presented as
mean  SD % of lymphocytes. **p < 0.01. IL ¼ interleukin; N ¼ healthy volunteers;
ns ¼ not signiﬁcant; PD ¼ programmed death; Pt ¼ cancer patients.
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(left panel) summarizes the results. In healthy volunteers, ganci-
clovir treatment tended to reduce IL-7Ra expression in PBMCs, but
the effect was not statistically signiﬁcant (control: 18.89 10.34 vs.
ganciclovir: 16.21  11.34% of lymphocytes; p ¼ 0.48). In cancer
patients, IL-7Ra expression was higher in the ganciclovir-treated
group (6.98  3% of lymphocytes) than in the untreated control
group (4.37  1.75% of lymphocytes; p < 0.01) (Fig. 2B, left panel).
These data indicate that upregulation of IL-7Ra following treatment
with ganciclovir might relate to the increases in the naive cell
proportions from cancer patients (Fig. 1B, upper left panel). Further
examination of the expression of PD-1, an inhibitory receptor of the
Ig superfamily reportedly expressed on exhausted CD8þ T cells
during chronic infection18, provided the results displayed in Fig. 2A
(lower panel, showing representative T cell PD-1 expression
following treatment) and Fig. 2B (right panel, summary of ﬁndings).
In healthy volunteers, T cell PD-1 expression in the ganciclovir-
treated group was signiﬁcantly lower than in the untreated
control group (control: 18.98 9.67 vs. ganciclovir: 11.43 5.83% of
lymphocytes; p < 0.01). However, data showed a slight decrease
but no differences in PD-1 expression between the ganciclovir-
treated cells (36.02  6.9% of total lymphocytes) and untreated
control cells (37.76  9.08% of total lymphocytes; p ¼ 0.59) from
patients with cancer (Fig. 2B, right panel).
3.3. Proportion of CD28þCD8þ T cells following ganciclovir
treatment
CD28 is a costimulatory molecule which is crucial for T cell acti-
vation19,20. Our previous study demonstrated that the proportion of
CD28þ T cells signiﬁcantly declined in cancer patients4. Therefore,
the present study examined the proportion of CD28þCD8þ T cells
from cancer patients following ganciclovir treatment. Fig. 3A shows
representative FACS plots of T cells following treatment; Fig. 3B
summarizes the results. The proportion of CD28þCD8þ T cells was
higher in the ganciclovir-treated group (16.35  6.83% of lympho-
cytes) than in the control group (13.26  5.85% of lymphocytes;
p < 0.05). These results indicate that there are slightly increased
proportions of IL-7Raþ and CD28þCD8þ T cells among the
ganciclovir-treated cells, which might be capable of undergoing
further differentiation and receiving stimulation for activity against
cancer and other pathogens.
3.4. Differential expression of IL-7Ra and PD-1 in ganciclovir-
treated cells following DC-A549 fusion cell stimulation
Given the potential of enhancing immune function by recon-
stitution of T cell subpopulations, the present study examined ifFig. 3. CD28/CD8 expression in ganciclovir-treated cells. Untreated control and ganciclovir-tr
CD8 antibodies to detect surface expression of CD28/CD8. (A) Representative FACS dot pl
CD28þCD8þ T cells in untreated control and ganciclovir-treated cells. Data are representat
*p < 0.05.ganciclovir-treated cells from cancer patients could demonstrate
improved responses following stimulation by antigen-presenting
cells (APCs), DC-A549 fusion cells, by pretreating PBMCs from
cancer patients with or without ganciclovir in vitro, then co-
culturing with DC-A549 fusion cells for 5 days.
Stimulation with DC-A549 fusion cells led to slight down-
regulation of IL-7Ra expression in the ganciclovir-treated group
(11.96  9.16% of lymphocytes) compared with the untreated
control group (16.07  11.29% of lymphocytes). This difference,
however, was not statistically signiﬁcant (p ¼ 0.09) (Fig. 4A). In
contrast, PD-1 expression signiﬁcantly decreased in the ganciclovir-
treated group (control: 45.7311.98 vs. ganciclovir: 34.3213.54%
of lymphocytes; p < 0.001) (Fig. 4B). Collectively, these results
indicate that ganciclovir-treated cells demonstrated improved
responses to stimulation by DC-A549 fusion cells.3.5. Enhanced cytotoxicity in ganciclovir-treated cells
The present study evaluated the antitumor activity of the
reconstituted T cell subsets following ganciclovir treatment by their
ability to kill allogeneic tumor cells. Coculture with DC-A549 fusion
cells stimulated ganciclovir-treated and untreated cells for 5 days.
Direct culture of both groups of cells with A549 cells for 8 hours
enabled the examination of allogeneic cytotoxic activity. Following
DC-A549 stimulation, ganciclovir-treated cells (14.49  15.56% of
lysis) displayed greater cytotoxic activity against A549 tumor cells
than untreated control cells (4.59  7.79% of lysis; p ¼ 0.0008)
(Fig. 5). These data indicate that treatment with ganciclovir
increases the T cell response to APCs stimulation and also restores T
cell antitumor activity.4. Discussion
In PBMCs from patients with cancer, in vitro treatment with
ganciclovir directly modiﬁed T cell subpopulations; speciﬁcally,
increasing the proportions of naive and effector populations and
considerably improving the antitumor activity of these cells.
Patients with advanced cancer who have received extensive treat-
ment have a signiﬁcantly impaired immune system, including
aberrant distribution of T cell subpopulations. Typically, patients
demonstrate decreases in naive and central memory T cells but
increases in the proliferation and differentiation of effector
memory cells4. These tendencies are indicative of T cell exhaus-
tion21. Tumors may evade the immune system using methods such
as downregulation of Major histocompatibility complex (MHC)
molecules or the antigen processing and presentation machinery,
increasing the secretion of inhibitory cytokines, and expressing co-eated cells from cancer patients (n ¼ 19) were further stained with anti-CD28 and anti-
ots of T cells in the presence or absence of ganciclovir treatment. (B) Percentages of
ive of ﬁve independent experiments and presented as mean  SD % of lymphocytes.
Fig. 4. Surface expression of (A) IL-7Ra and (B) PD-1 in ganciclovir-treated cells
following stimulation with DC-A549 fusion cells. Groups of cells (untreated control and
ganciclovir-treated cells) from cancer patients were stimulated using DC-A549 fusion
cells (n ¼ 12e16/group), and then further stained with anti-IL-7Ra and anti-PD-1
antibodies to detect surface expression of IL-7Ra and PD-1. Percentages of IL-7Raþ
and PD-1T cells in untreated control and ganciclovir-treated groups are shown. The
data are presented as mean  SD % of lymphocytes. ***p < 0.001. DC ¼ dendritic cells;
IL ¼ interleukin; ns ¼ not signiﬁcant; PD ¼ programmed death.
Ganciclovir Improves Immune Status 175inhibitory molecules22e25. Our previous study suggested another
possiblemechanism bywhich the immune system fails to eliminate
the tumor; failure to activate the appropriate lymphocytes to the
threshold required for tumor rejection4. To effectively treat cancers,
it is therefore essential to restore compromised immunity. In the
present study, the total proportion of effector plus effector memory
cells remained lower in ganciclovir-treated cells than in untreated
cells. Therefore, increasing the proportion of naive T cells and
decreasing the proportion of effector memory T cells by treating
with ganciclovir may have enhanced the capacity for tumor killing.
IL-7 is an essential factor for naive T cell survival and prolifer-
ation26. However, previous research has shown that decreasing
naive T cell populations in patients with cancer was associated with
downregulation of IL-7Ra, but not of plasma IL-7 levels. The present
study demonstrated signiﬁcant increases in naive T cells following
ganciclovir treatment. Data further demonstrated that the
proportions of IL-7Raþ and CD28þCD8þ Tcells from cancer patients
can increase mildly following treatment of the cells with ganci-
clovir. CD28 is a critical component of the adaptive immune
response against infections and tumors. Full activation of T cells
requires T cell receptor engagement and costimulatory molecules
present on the surface of the APCs. Increases in proportions of
CD28þCD8þ and naive T cells after treatment indicate that greater
numbers of functional T cells were ready to communicate with the
APCs, and therefore have greater opportunity to generate tumor-
speciﬁc T cells. To verify this, the present study investigated the
antitumor function of the reconstituted Tcell populations following
treatment with ganciclovir. DC-A549 fusion cells, as professional
APCs, stimulated speciﬁc T cell function against tumor cells.
Following antigen presentation, ganciclovir-treated T cellsFig. 5. Cytotoxicity of ganciclovir-treated cells against A549 tumor cells. Cells (n ¼ 16)
from two groups (control and ganciclovir treatment) described in Fig. 3 were stimu-
lated using DC-A549 fusion cells for 5 days. After stimulation by the DC-A549 fusion
cells, cytotoxic effects on A549 tumor cells were tested using a 10:1 effector-to-target
(E/T) ratio. Percentage of lysis was determined as described in Materials and methods.
The data are presented as mean  SD % of lysis from ﬁve independent experiments.
***p < 0.001. DC ¼ dendritic cells.displayed signiﬁcantly greater cytotoxic activity against A549 cells
than untreated control cells. The mean cytotoxic capacity of the
ganciclovir-treated cells was 3.16-fold higher than that of the
untreated control cells. These data indicate that treatment with
ganciclovir restored T cell function, allowing for efﬁcient lysis of
tumor cells.
Results from investigation of PD-1 expression, which is usually
on exhausted T cells27, indicated that PD-1 upregulation may
exhaust CD8þ Tcell function, facilitating viral persistence in chronic
viral infection28. In the present study, the expression of PD-1 did
not decrease following treatment with ganciclovir alone, but it
downregulated after stimulation of treated cells with DC-A549
fusion cells (Fig. 2B and Fig. 4B). DC-A549 fusion cells may acti-
vate the reconstituted T cells and subsequently trigger PD-1
downregulation. This, in turn, reverses T cell exhaustion, allowing
the cells to target and eliminate cancer cells. The underlying
mechanism for this phenomenon requires further investigation.
Previous studies have demonstrated that the PD-1/PD-L1 system
plays a signiﬁcant role in regulating the CD8 T cell response29, and
that blockade of PD-1/PD-L1 interaction reversed T cell exhaus-
tion18. Recently, a fully human IgG4 monoclonal antibody against
PD-1 (MDX-1106) completed a phase I clinical trial in patients with
a variety of solid tumors30. The patients tolerated the treatment
well and investigators reported a few partial tumor responses.
These studies suggest that blockade of PD-1/PD-L1 interaction
might reverse T cell exhaustion. A full understanding of PD-1 signal
transduction is important for elucidating the molecular mecha-
nisms behind Tcell exhaustion, andmay reveal ways of overcoming
T cell exhaustion, enabling clearance of chronic infection and
tumors.
Collectively, results from this study indicate that PBMCs from
cancer patients treated with ganciclovir demonstrate changes in
the distribution of T cell subpopulations, including early differen-
tiated T cells, leading to upregulation of IL-7Raþ and CD28þCD8þ
subpopulations and increased T cell cytotoxity against tumor cells.
The downregulation of PD-1 following stimulation by APCs might
indicate reversal of T cell exhaustion. Despite ganciclovir directly
impeding T cell proliferation12,13, the present study demonstrates
that ganciclovir treatment improved immune function in T cells
from cancer patients. Pre-emptive anti-CMV treatment could,
therefore, have potential use as an adjunct in cancer treatment,
especially during chemotherapy. The shift in T cell distribution
following ganciclovir treatment suggests that treatment of reac-
tivated CMV infection may inhibit virus replication and also
contribute to amelioration of the immune deﬁciency observed in
cancer patients, by increasing the proportion of early functional T
cells and decreasing the proportion of late hyporesponsive T cells.
So far, to our knowledge, there have been no reports of ganciclovir
for restoring T cell exhaustion in vivo. More detailed animal study is
underway and hopefully will clarify these issues. If the present
study’s in vitro ﬁndings also apply in vivo, antiviral treatment in
patients with cancer may help to achieve optimal results from
chemotherapy or immunotherapy.
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